Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis by Huang, Wei et al.
1	
	
1	
	
Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- 
and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis 
Wei Huang1,2, Andrea C. Haynes4, Rajarshi Mukherjee1,2, Li Wen1,2, Diane Latawiec1,2, Alexei V. Tepikin2,4, 
David N. Criddle2,4, Rab K. Prinjha3, Nicholas Smithers3, Robert Sutton1,2 
1Department of Molecular and Clinical Cancer Medicine,2NIHR Liverpool Pancreas Biomedical Research Unit, 
Royal Liverpool University Hospital and 3Cellular and Molecular Physiology, Institute of Translational 
Medicine, University of Liverpool, Liverpool, UK, and 4Immuno-Inflammation Therapeutic Area Unit, 
GlaxoSmithKline, Stevenage, UK. 
Running title: BET proteins in experimental acute pancreatitis 
Acknowledgements: This study was supported by a grant from GlaxoSmithKline plc, UK/China Postgraduate 
Research Scholarship for Excellence (W.H.), Liverpool China Scholarship Council Award (L.W.), CORE, UK 
(R.M.), UK Medical Research Council (A.V.T., D.N.C., R.S.) and the UK National Institute for Health 
Research Biomedical Research Unit Funding Scheme (D.L., A.V.T., R.S.). The authors thank the Quantitative 
Pharmacology Group (Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline, Stevenage, UK) for 
pharmacokinetic and analytical support. 
Abbreviations: AP, acute pancreatitis; AUC, area under the curve; BET proteins, bromodomain and extra-
terminal proteins; CCL2, chemokine (C-C motif) ligand 2; CER-AP, caerulein-induced AP; Cmax, peak serum 
concentration; CXCL1, chemokine (C-X-C motif) ligand 1; DMSO, dimethyl sulfoxide; FAEE-AP, fatty acid 
ethyl ester-induced AP; HETAB, hexadecyltrimethyl ammonium bromide; IL, interleukin; i.p., intraperitoneal; 
MOPS, 3-(N-morpholino)propanesulfonic acid; MPO, myeloperoxidase; POA, palmitoleic acid; TLCS-AP, 
taurolithocholic acid 3-sulphate disodium salt-induced AP; Tmax, time of Cmax; TMB, 3,3’,5,5’-
tetramethylbenzidine. 
Author contributions: R.S. A.C.H and N.S. conceived the study; R.S. designed and supervised the study. R.S., 
A.V.T., D.N.C., W.H., R.M. and L.W. obtained funding. W.H., R.M., L.W., D.L., A.C.H., and R.K.P. acquired 
and analysed the data. W.H., A.C.H. and R.S. wrote the paper. A.V.T., D.N.C. A.C.H., R.K.P. and N.S. 
undertook critical revision of the manuscript for important intellectual content.  
Conflicts of interest: This study was supported financially by GlaxoSmithKline plc. A.C.H., R.K.P., and N.S. 
are employees of GlaxoSmithKline plc. 
 
Correspondence to Robert Sutton, DPhil, FRCS, NIHR Liverpool Pancreas Biomedical Research Unit, 5th Floor 
UCD Block, Royal Liverpool University Hospital, University of Liverpool, Liverpool L69 3GA, UK. Phone: 
+44 (0)151 706 4877 Fax: +44 (0)151 706 5826 Email: r.sutton@liverpool.ac.uk 
2	
	
2	
	
ABSTRACT 
Objectives: To evaluate the therapeutic potential of I-BET-762, an inhibitor of the bromodomain and extra-
terminal (BET) protein family, in experimental acute pancreatitis (AP).  
Methods: AP was induced by retrograde infusion of taurolithocholic acid sulphate into the biliopancreatic duct 
(TLCS-AP) or two intraperitoneal (i.p.) injections of ethanol and palmitoleic acid 1 h apart (FAEE-AP) or 12 
hourly i.p. injections of caerulein (CER-AP). In all treatment groups, I-BET-762 (30 mg/kg, i.p.) was 
administered at the time of disease induction and again 12 h later. AP severity was assessed at 24 h by serum 
biochemistry, multiple cytokines and histopathology.  
Results: TLCS-AP, FAEE-AP and CER-AP resulted in characteristic elevations in serum amylase and cytokine 
levels, increased pancreatic trypsin and myeloperoxidase activity, typical pancreatic histopathological changes 
and lung injury. Treatment with I-BET-762 significantly reduced biochemical, cytokine and histopathological 
responses in TLCS-AP and FAEE-AP, but not CER-AP.   
Conclusions: These results suggest that in different forms of AP there are significant differences in the 
epigenetic control of gene transcription contributing to the severity of disease responses. There is therapeutic 
potential in targeting bromodomains for the treatment of gallstone- and alcohol-related pancreatitis. 
Key words: acute pancreatitis, epigenetics, BET inhibition, drug discovery  
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INTRODUCTION 
AP is an inflammatory condition of the pancreas with an incidence of 30-50 cases per 100,000 population per 
year and an overall mortality of circa 5% in the Western world1, for which there is no licensed treatment. 
Gallstones and alcohol excess account for about 80% of AP aetiology2. 15-20% of all patients suffer a severe 
illness in which two broad phases can be identified. Within the first 7 to 10 days after onset of a severe attack 
there is a pro-inflammatory phase featuring pancreatic injury and systemic inflammatory response syndrome 
that may result in organ failure, during which time pancreatic necrosis frequently develops. Subsequently there 
is relative immune anergy, which may result from earlier over-activation or disruption of the immune system. 
During this later phase peri-pancreatic necrotic or systemic infections are more likely to develop and contribute 
to a worse outcome3, 4. Strategies that inhibit the early phase immune response in AP that also sustain 
subsequent immune function hold significant promise in drug discovery for AP. 
 
Histones surround DNA in nucleosomes and contribute to the regulation of gene expression through epigenetic 
post-translational histone modifications specific to individual cells, including through acetylation, methylation, 
citrullination and phosphorylation. These post-translational modifications, termed epigenetic marks, facilitate 
the formation of macromolecular protein complexes that relax condensed nuclear DNA, increasing 
transcription5. Bromodomain and extra-terminal (BET) proteins (BRD2, BRD3, BRD4 and BRDT) form these 
complexes through binding to epigenetic marks, notably acetylated lysine residues6, reducing interaction 
between histones and DNA, thus increasing transcription. I-BET-762 (also known as GSK525762A) is a potent 
inhibitor of the BET family of proteins that has been shown to be protective in a lethal model of infection in 
vivo6 and in CD4+ T-cell-mediated neuroinflammation7, and is now in early phase trials for oncological 
indications8. Since the immune response is a critical contributor to pancreatic and systemic injury in AP, and I-
BET-762 might be a potential treatment for AP, we sought to determine the local and systemic effects of I-BET-
762 in multiple experimental models of AP.   
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MATERIALS AND METHODS 
Experimental animals  
Male CD1 mice (30-35 g), purchased from Charles River UK Ltd (Margate, UK), were housed at 23 ± 2°C 
under a 12 h light/dark cycle with ad libitum access to standard laboratory chow and water. Twelve hours before 
induction of AP, the animals were deprived of food but were allowed access to water; 2 h after initiation of 
experimental procedures (which took less than 1 h), food was returned to animals.  Studies were conducted in 
compliance with UK Home Office regulations (PPL 40/3320, renewed as 70/8109), together with the 
Institutional Ethical Review processes of the University of Liverpool.  
Induction of AP and adminstration of I-BET-762 
AP was induced using 3 different methods: (i) Retrograde infusion of 3 mM taurolithocholic acid 3-sulphate 
disodium salt (TLCS) was injected at a speed of 5 µl/min for 10 min into the biliopancreatic duct (with a clamp 
across the upper end) by minipump (Harvard Apparatus, Kent, UK) to induce TLCS-AP9, 10; control mice 
received the same surgical procedure but with infusion of normal saline, not TLCS. (ii) Two intraperitoneal 
(i.p.) injections of ethanol (1.35 g/kg) and palmitoleic acid (POA, 150 mg/kg) were administered 1 h apart to 
cause fatty acid ethyl ester-induced AP (FAEE-AP)11-14; control mice received 2 i.p. injections of either saline or 
ethanol. To avoid local damage by ethanol to the peritoneal organs at the injection site, 150 µL of saline was 
injected i.p. shortly before the ethanol/POA injections. (iii) Hyperstimulation by 12 hourly i.p. injections of 
cerulein (50 µg/kg, CER-AP)14, 15, a cholecystokinin analog16, while control mice received 12 saline injections 
(i.p.).  At the time of disease induction, analgesia was administered by subcutaneous administration of 
buprenorphine hydrochloride (0.1 mg/kg). 
Mice received 2 i.p. injections of either I-BET-762 (30 mg/kg) or vehicle (2% dimethyl sulfoxide (DMSO)/98% 
kleptose (10%) solution): the first was administered at the time of disease induction and the second 12 h later.  
Mice were humanely killed at 24 h and blood, pancreas and lung tissue immediately sampled to assess disease 
severity14. 
Serum amylase and circulating cytokines 
Blood samples were allowed to clot naturally (serum) or were preserved in ethylenediaminetetraacetic acid 
(EDTA) tubes (plasma) for 30 min, followed by centrifugation at 1,500 g × 10 min. Serum amylase was 
measured kinetically using a Roche automated clinical chemistry analyser (GMI, Leeds, UK).  
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Serum or plasma multicytokine tests for interleukin- (IL-) 1β, IL-10, chemokine (C-C motif) ligand 2 (CCL2) 
and chemokine (C-X-C motif) ligand 1 (CXCL1) were carried out according to the protocols provided by R&D 
Systems (Abingdon, UK) using a Bio-Rad luminex machine (Hemel Hempstead, UK). IL-6 was measured using 
Quantikine ELISA according to the instructions provided by R&D Systems. 
Pancreatic trypsin activity 
Pancreata were homogenised in tissue buffer (pH 6.5), containing 3-(N-morpholino)propanesulfonic acid 
(MOPS, 5 mM), sucrose (250 mM) and magnesium sulfate (1 mM) using a motorised homogeniser on ice. The 
homogenates were centrifuged at 1,500 g for 5 min, and 100 µL of each supernatant were added to a cuvette 
containing the peptide substrate Boc-Gln-Ala-Arg-MCA (Peptide, Osaka, Japan) dissolved in 1900 µL assay 
buffer (pH 8.0) containing Tris (50 mM), NaCl (150 mM), CaCl2 (1 mM) and 0.1 mg/mL bovine serum 
albumin. Trypsin activity was measured fluorimetrically using a Shimadzu RF-5000 spectrophotometer (Milton 
Keynes, UK; excitation 380 nm, emission 440 nm17). Standard curves were generated using purified human 
trypsin. Pancreatic protein concentration was measured by a BCA protein assay (Thermo, Rockford, USA) using 
a BMG FLUOstar Omega Microplate Reader (Imgen Technologies, New York, USA). Trypsin activity was 
expressed as fmol/mg protein. 
Pancreatic and lung myeloperoxidase (MPO) activity 
Pancreatic and lung MPO activity were tested by a modified method from Dawra et al18. Pancreatic tissue was 
homogenized, resuspended in 100 mM potassium phosphate buffer (pH 5.4) containing 0.5% 
hexadecyltrimethyl ammonium bromide (HETAB), 10 mM EDTA and protease inhibitors, freeze-thawed three 
times, sonicated for 30 sec and centrifuged for 15 min at 16,000 g. MPO activity was measured using substrate 
3,3’,5,5’-tetramethylbenzidine (TMB). Briefly, 20 µL of the supernatant were added to the assay mix, which 
consisted of 200 µL of phosphate buffer (100 mM, pH 5.4) with 0.5% HETAB and 20 µl TMB (20 mM in 
DMSO). This mixture was incubated at 37°C for 3 min, followed by addition of 50 µL H2O2 (0.01%), then 
incubated for another 3 min. The difference in absorbance between 0 min and 3 min at 655 nm was calculated 
from a human MPO standard curve using a plate reader. MPO activity was expressed as mU/mg protein.  
Histopathology 
After H&E staining of the pancreas, 10 random fields per slide (5 µm) from all groups were graded by two 
independent blinded observers according to the severity and extent of oedema, inflammatory cell infiltration and 
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acinar necrosis (magnification × 200) as described by Wildi et al19. Similarly for the lung sections, 10 random 
fields per slide were scored according to the following thickening of alveolar septae: normal = 0, thickening 
<1/3 field = 1, thickening = 1/3 - 2/3 field = 2 and thickening >2/3 field = 3 (magnification × 200). 
Pharmacokinetic analysis 
Terminal blood (25 µL) was collected from satellite mice with TLCS-AP and CER-AP at 0.25, 1, 2, 4, 12.25 
and 24 h after the first injection of I-BET-762 (n = 1 per time point for each model).  An equal volume of water 
(25 µL) was added to the blood, mixed and frozen prior to measurement of blood levels of I-BET-762 by liquid 
chromatography-tandem mass spectrometry at GSK Stevenage (UK).  
Drugs and chemicals 
I-BET-762 (synthesised at GSK Stevenage UK) was dissolved in 2% DMSO/98% kleptose (10%) solution and 
dosed as the free base at 30 mg/kg in a dose volume of 10 mL/kg. TLCS, ethanol, POA, caerulein, human 
trypsin, human MPO, TMB and other chemicals if not otherwise stated were purchased from Sigma 
(Gillingham, UK). 
Data analysis 
Results were presented as mean ± SE obtained from three or more independent experiments. In all the figures, 
vertical bars denote SE values. A Student’s t-test was used for statistical evaluation of data with a normal 
distribution, while an ANOVA test was carried out for data with a skewed distribution. P values of < 0.05 were 
considered to indicate significant differences. 
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RESULTS 
Pharmacokinetics analysis of I-BET-762 in TLCS-AP and CER-AP 
Analysis of the blood samples following the first 30 mg/kg (i.p.) injection of I-BET-762 in the TLCS-AP and 
CER-AP models gave peak serum concentrations (Cmax) of 26.68 and 10.61 µg/mL at 0.25 h (time of Cmax, 
Tmax) with resulting exposures (area under the curve, AUC0-inf) of 42.03 and 19.91 µg.h/mL respectively 
(Table 1). Blood concentrations in both models were within the expected range following single administration 
over the first 12 h6. 
Effects of I-BET-762 in TLCS-AP 
Infusion of 3 mM (50 µL) TLCS into the pancreatic duct caused marked increases in serum amylase and 
pancreatic MPO (Figures 1A, B). TLCS infusion also resulted in significant increases in serum cytokines (IL-6, 
IL-10, CCL2 and CXCL1; Table 2) and lung injury that was evident in an elevated lung MPO (Figure 1C) and 
thickened alveolar septae (TLCS-AP 1.16 ± 0.06 versus sham 0.22 ± 0.05, P < 0.05). There were pronounced 
histopathological findings in the head of pancreas at 24 h demonstrated by oedema, vacuolisation, inflammatory 
cell infiltration and scattered necrosis (Figure 2A). Consistent with the known features of this model10, 12-14, 20, 
the body and tail of the pancreas were less affected (data not shown). The severity of pancreatic histopathology 
was reflected in a significant increase in the overall histopathological score and the individual components 
compared to the sham group (Figure 2B). I-BET-762 administration significantly reduced serum amylase and 
showed a trend to lower pancreatic MPO (Figures 1A, B). Moreover, I-BET-762 significantly lowered serum 
cytokines (IL-6, IL-10, CCL2 and CXCL1; Table 2). I-BET-762 significantly reduced the overall pancreatic 
histopathological score and oedema score, with a trend to curtail the inflammation and necrosis scores (Figures 
2A, B). Furthermore, lung MPO (Figure 1C) and alveolar septal thickening (TLCS-AP with I-BET-762 0.55 ± 
0.11 versus TLCS-AP without I-BET-762 1.16 ± 0.06, P < 0.05) were significantly diminished with I-BET-762 
treatment.  
Effects of I-BET-762 in FAEE-AP 
Concomitant i.p. injections of ethanol and POA induced a pronounced rise in serum amylase, pancreatic trypsin 
and MPO levels (Figures 3A, B and C). Moreover, plasma cytokines (IL-6, IL-10, CCL2 and CXCL1; Table 
3), lung MPO (Figure 3D) and alveolar septal thickening (FAEE-AP 2.05 ± 0.19 versus saline 0.41 ± 0.1, P < 
0.01) were significantly increased in FAEE-AP. FAEE-AP caused changes in the pancreas as in TLCS-AP, but 
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in contrast to TLCS-AP, the changes were not restricted to the head of the pancreas (Figure 4A) and were 
pronounced (Figure 4B). Treatment of FAEE-AP with I-BET-762 significantly reduced serum amylase, 
pancreatic trypsin and myeloperoxidase (Figures 3A, B, C). Moreover, I-BET-762 diminished serum cytokines 
(IL-6, IL-10, CCL2 and CXCL1; Table 3) but had no significant effect on lung injury. The overall pancreatic 
histopathological score was also greatly ameliorated by I-BET-762, showing significant reductions in oedema 
and inflammation scores with a trend to decrease the necrosis score (Figure 4B). 
Effects of I-BET-762 in CER-AP 
Hyperstimulation of the pancreas with 12 hourly i.p. injections of supramaximal caerulein caused typical 
features of AP at 24 h as shown by raised serum amylase, pancreatic trypsin and MPO (Figure 5A-C), serum 
cytokines (IL-6, CCL2 and CXCL1; Table 4) and lung injury with raised lung MPO (Figures 5D) and alveolar 
septal thickening (caerulein 1.75 ± 0.19 versus saline 0.38 ± 0.13, P <0.01), as well as overall pancreatic 
histopathology score (Figure 6A, B). The histopathological changes in pancreatic oedema, inflammation and 
necrosis appeared more pronounced and more homogenously distributed compared to TLCS-AP and FAEE-AP 
(Figure 6A).  
Treatment with I-BET-762 did not have protective effects on serum amylase, pancreatic trypsin, pancreatic 
MPO, pancreatic histopathology or lung injury, but rather caused a modest increase of all parameters measured. 
Interestingly, I-BET-762 significantly increased serum cytokines (IL-6, IL-10, CCL2 and CXCL1). As these 
results were inconsistent with the effects of I-BET-762 in TLCS-AP and FAEE-AP, the experiments were 
repeated by an independent investigator (L.W.). These further experiments were conducted with CER-AP 
induced by either 7 or 12 hourly i.p. injections of caerulein (50 µg/kg) in separate groups; identical results were 
obtained with modest increases in all parameters as a result of I-BET762 (data not shown), as before. 
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DISCUSSION 
Here we have shown that I-BET-762 significantly reduces pancreatic damage and systemic injury in 2 
experimental models representing the commonest causes of clinical AP, namely gallstones and alcohol excess, 
although not in hyperstimulation AP, a rare cause. These findings broaden the potential applications of BET 
protein inhibition across inflammatory diseases, while ongoing clinical trials assess applications in oncology, 
cardiovascular disease, diabetes mellitus and dyslipidaemia21. I-BET-762 has been shown to inhibit transcription 
of multiple inflammatory response genes induced in macrophages by lipopolysaccharide, conferring protection 
against death from lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis from caecal 
puncture in murine models6. The inhibitory action of I-BET-762 is highly specific, not affecting genes already 
primed for or actively involved in transcription as primary immune response genes, but greatly reducing 
transcription of secondary immune response genes6. Thus I-BET-762 has not previously been found to inhibit 
transciption of tumour necrosis factor but inhibits transcription of IL-66. The resulting inhibition of the 
biochemical, immunological and histopathological features of TLCS-AP and FAEE-AP confirm that the 
severity of these models is determined at least in part by immune responses depending directly on transcription. 
Transcription of other genes that contribute to the severity of AP may have been inhibited, and not necessarily 
the same genes in the 2 models, although the overall impact of I-BET-762 was similar in both. Thus BET 
inhibition could have clinical application since AP, like severe sepsis, is characterised by organ failure induced 
by profound systemic inflammatory responses; inhibition of these responses may reduce organ dysfunction 
while maintaining later phase immune competence. 
 
The absence of any protective effect from I-BET-762 on the severity of CER-AP indicates that the mechanisms 
by which transcription contributes to severity in CER-AP have important differences from those in TLCS-AP 
and FAEE-AP. This is despite achieving pharmacologically relevant blood concentrations within the range 
required to see in vivo efficacy6, 8, 21, albeit lower in CER-AP than TLCS-AP. Were the mechanisms to be the 
same, at least a modest beneficial effect from I-BET-762 in CER-AP would be expected. Several differences 
could be present, as suggested by the far lower levels of several cytokines in CER-AP than in TLCS-AP and 
FAEE-AP, despite the severity of CER-AP induced with 12 caerulein injections, and the increase in these levels 
in CER-AP following I-BET-762 administration. Administration of I-BET-762 in CER-AP enhanced expression 
of IL-6, IL-10, CCL2 and CXCL1, possibly from enhanced transcription of other genes through compensatory 
mechanisms in the macromolecular regulation of transcription following BET protein inhibition, including 
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histone acetylation-independent mechanisms. Histone phosphorylation contributes to the severity of CER-AP22, 
likely more so than in TLCS-AP and FAEE-AP23, and may render I-BET-762 ineffective in preventing BET 
protein binding to histones, as I-BET-762 is an acetylated histone mimic. The contribution of immune responses 
to CER-AP may depend more on the direct effects of primary immune response genes, such as those induced by 
tumour necrosis factor receptor type 1 ligation, which triggers receptor interacting protein kinase activation and 
susequent necroptosis24. The marked pancreatic histopathological changes in CER-AP with far lower levels of 
IL-6, IL-10, CCL2 and CXCL1 than in TLCS-AP and FAEE-AP suggest that secondary immune response genes 
have a relatively reduced role in CER-AP. Alternatively I-BET762 when administered with caerulein might 
have an unknown off-target effect that exacerbates AP. Further exploration of these differences would benefit 
from detailed comparative transcriptomic analyses at different time points following induction of AP in each 
model, with and without I-BET-762. Nevertheless the markedly contrasting results of I-BET-762 administration 
in these three models do illustrate the complexity of epigenetic control of gene transcription in AP. This is 
despite common mechanisms of pancreatic injury that include intracellular calcium overload11-14, 25, 26, reactive 
oxygen species production27, mitochondrial injury11, 13, 28, trypsinogen activation29, 30, nuclear factor-κB 
activation31 and induction of the inflammasomes32.  
In both TLCS-AP and FAEE-AP the most marked effect of I-BET-762 was to ablate markedly raised levels of 
IL-6, IL-10, CCL2 and CXCL1. These results are consistent with previous data showing that inhibition of 
pancreatic histone acetyltransferases by pentoxifylline ameliorates the severity of taurocholate-induced AP in 
rats33, although pentoxyfylline has other effects that may be protective in AP, including inhibition of tumour 
necrosis factor alpha production34. The inhibition of IL-10 production by I-BET-762 in TLSC-AP and FAEE-
AP removes an immunoregulator, but that occurred alongside the reduction of major pro-inflammatory 
cytokines including IL6, which is associated with lung injury and lethality35. The effects of I-BET-762 on 
cytokine responses in these 2 models implicates post-translational modification of histones in the disease course 
of AP and confirms the validity of a strategy to prevent the consequences of pancreatic and leukocyte histone 
acetylation in the search for new, effective treatments in clinical AP. 
11	
	
11	
	
REFERENCES 
1 Roberts SE, Akbari A, Thorne K, Atkinson M, Evans PA: The incidence of acute pancreatitis: Impact 
of social deprivation, alcohol consumption, seasonal and demographic factors. Alimentary pharmacology & 
therapeutics 2013; 38: 539-548. 
2 Frossard JL, Steer ML, Pastor CM: Acute pancreatitis. Lancet 2008; 371: 143-152. 
3 Mayerle J: A novel role for leucocytes in determining the severity of acute pancreatitis. Gut 2009; 58: 
1440-1441. 
4 Tenner S, Baillie J, DeWitt J, Vege SS, American College of G: American college of gastroenterology 
guideline: Management of acute pancreatitis. The American journal of gastroenterology 2013; 108: 1400-1415; 
1416. 
5 Escobar J, Pereda J, Lopez-Rodas G, Sastre J: Redox signaling and histone acetylation in acute 
pancreatitis. Free Radic Biol Med 2012; 52: 819-837. 
6 Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW et al.: Suppression of 
inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123. 
7 Bandukwala HS, Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ et al.: Selective inhibition 
of cd4+ t-cell cytokine production and autoimmunity by bet protein and c-myc inhibitors. Proc Natl Acad Sci U 
S A 2012; 109: 14532-14537. 
8 Mirguet O, Gosmini R, Toum J, Clement CA, Barnathan M, Brusq JM et al.: Discovery of epigenetic 
regulator i-bet762: Lead optimization to afford a clinical candidate inhibitor of the bet bromodomains. J Med 
Chem 2013; 56: 7501-7515. 
9 Perides G, van Acker GJ, Laukkarinen JM, Steer ML: Experimental acute biliary pancreatitis induced 
by retrograde infusion of bile acids into the mouse pancreatic duct. Nat Protoc 2010; 5: 335-341. 
10 Perides G, Laukkarinen JM, Vassileva G, Steer ML: Biliary acute pancreatitis in mice is mediated by 
the g-protein-coupled cell surface bile acid receptor gpbar1. Gastroenterology 2010; 138: 715-725. 
11 Huang W, Booth DM, Cane MC, Chvanov M, Javed MA, Elliott VL et al.: Fatty acid ethyl ester 
synthase inhibition ameliorates ethanol-induced ca2+-dependent mitochondrial dysfunction and acute 
pancreatitis. Gut 2014; 63: 1313-1324. 
12 Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D et al.: Inhibitors of orai1 prevent 
cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models. 
Gastroenterology 2015; 149: 481-492 e487. 
12	
	
12	
	
13 Mukherjee R, Mareninova OA, Odinokova IV, Huang W, Murphy J, Chvanov M et al.: Mechanism of 
mitochondrial permeability transition pore induction and damage in the pancreas: Inhibition prevents acute 
pancreatitis by protecting production of atp. Gut 2015. 
14 Huang W, Cane MC, Mukherjee R, Szatmary P, Zhang X, Elliott V et al.: Caffeine protects against 
experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated ca2+ release. Gut 
2015. 
15 Ou X, Cheng Z, Liu T, Tang Z, Huang W, Szatmary P et al.: Circulating histone levels reflect disease 
severity in animal models of acute pancreatitis. Pancreas 2015; 44: 1089-1095. 
16 Saluja AK, Lerch MM, Phillips PA, Dudeja V: Why does pancreatic overstimulation cause 
pancreatitis? Annu Rev Physiol 2007; 69: 249-269. 
17 Nathan JD, Romac J, Peng RY, Peyton M, Macdonald RJ, Liddle RA: Transgenic expression of 
pancreatic secretory trypsin inhibitor-i ameliorates secretagogue-induced pancreatitis in mice. Gastroenterology 
2005; 128: 717-727. 
18 Dawra R, Ku YS, Sharif R, Dhaulakhandi D, Phillips P, Dudeja V et al.: An improved method for 
extracting myeloperoxidase and determining its activity in the pancreas and lungs during pancreatitis. Pancreas 
2008; 37: 62-68. 
19 Wildi S, Kleeff J, Mayerle J, Zimmermann A, Bottinger EP, Wakefield L et al.: Suppression of 
transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted 
stimulation at high caerulein concentrations. Gut 2007; 56: 685-692. 
20 Huang W, Cash N, Wen L, Szatmary P, Mukherjee R, Armstrong J et al.: Effects of the mitochondria-
targeted antioxidant mitoquinone in murine acute pancreatitis. Mediators Inflamm 2015; 2015: 901780. 
21 Ferri E, Petosa C, McKenna CE: Bromodomains: Structure, function and pharmacology of inhibition. 
Biochem Pharmacol 2015. 
22 Mahajan UM, Gupta C, Wagh PR, Karpe PA, Tikoo K: Alteration in inflammatory/apoptotic pathway 
and histone modifications by nordihydroguaiaretic acid prevents acute pancreatitis in swiss albino mice. 
Apoptosis 2011; 16: 1138-1149. 
23 Voronina SG, Barrow SL, Simpson AW, Gerasimenko OV, da Silva Xavier G, Rutter GA et al.: 
Dynamic changes in cytosolic and mitochondrial atp levels in pancreatic acinar cells. Gastroenterology 2010; 
138: 1976-1987. 
13	
	
13	
	
24 He S, Wang L, Miao L, Wang T, Du F, Zhao L et al.: Receptor interacting protein kinase-3 determines 
cellular necrotic response to tnf-alpha. Cell 2009; 137: 1100-1111. 
25 Husain SZ, Orabi AI, Muili KA, Luo Y, Sarwar S, Mahmood SM et al.: Ryanodine receptors 
contribute to bile acid-induced pathological calcium signaling and pancreatitis in mice. Am J Physiol 
Gastrointest Liver Physiol 2012; 302: G1423-1433. 
26 Jin S, Orabi AI, Le T, Javed TA, Sah S, Eisses JF et al.: Exposure to radiocontrast agents induces 
pancreatic inflammation by activation of nuclear factor-kappab, calcium signaling, and calcineurin. 
Gastroenterology 2015; 149: 753-764 e711. 
27 Booth DM, Murphy JA, Mukherjee R, Awais M, Neoptolemos JP, Gerasimenko OV et al.: Reactive 
oxygen species induced by bile acid induce apoptosis and protect against necrosis in pancreatic acinar cells. 
Gastroenterology 2011; 140: 2116-2125. 
28 Shalbueva N, Mareninova OA, Gerloff A, Yuan J, Waldron RT, Pandol SJ et al.: Effects of oxidative 
alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of 
alcoholic pancreatitis. Gastroenterology 2013; 144: 437-446 e436. 
29 Gaiser S, Daniluk J, Liu Y, Tsou L, Chu J, Lee W et al.: Intracellular activation of trypsinogen in 
transgenic mice induces acute but not chronic pancreatitis. Gut 2011; 60: 1379-1388. 
30 Dawra R, Sah RP, Dudeja V, Rishi L, Talukdar R, Garg P et al.: Intra-acinar trypsinogen activation 
mediates early stages of pancreatic injury but not inflammation in mice with acute pancreatitis. 
Gastroenterology 2011; 141: 2210-2217 e2212. 
31 Huang H, Liu Y, Daniluk J, Gaiser S, Chu J, Wang H et al.: Activation of nuclear factor-kappab in 
acinar cells increases the severity of pancreatitis in mice. Gastroenterology 2013; 144: 202-210. 
32 Hoque R, Sohail M, Malik A, Sarwar S, Luo Y, Shah A et al.: Tlr9 and the nlrp3 inflammasome link 
acinar cell death with inflammation in acute pancreatitis. Gastroenterology 2011; 141: 358-369. 
33 Sandoval J, Escobar J, Pereda J, Sacilotto N, Rodriguez JL, Sabater L et al.: Pentoxifylline prevents 
loss of pp2a phosphatase activity and recruitment of histone acetyltransferases to proinflammatory genes in 
acute pancreatitis. J Pharmacol Exp Ther 2009; 331: 609-617. 
34 Pereda J, Sabater L, Cassinello N, Gomez-Cambronero L, Closa D, Folch-Puy E et al.: Effect of 
simultaneous inhibition of tnf-alpha production and xanthine oxidase in experimental acute pancreatitis: The 
role of mitogen activated protein kinases. Ann Surg 2004; 240: 108-116. 
14	
	
14	
	
35 Zhang H, Neuhofer P, Song L, Rabe B, Lesina M, Kurkowski MU et al.: Il-6 trans-signaling promotes 
pancreatitis-associated lung injury and lethality. J Clin Invest 2013; 123: 1019-1031. 
 
 
 
15	
	
15	
	
TABLES 
 
Table 1. Blood concentrations of I-BET-762 in male CD1 mice with TLCS-AP or CER-AP following 
intraperitoneal administration every 12 h at a target dose of 30 mg/kg. The first injection was administered at the 
time of disease induction, and a composite profile was achieved with n = 1 mouse per time-point. (A) Blood 
concentration at each time-point. (B) Pharmacokinetic parameters. 
 
A.  
I-BET-762 concentration 
(µg/mL) 
Time 
(h) 
CER-AP TLCS-AP 
0.25 10.610 26.676 
1.00 8.542 11.302 
2.00 3.417 8.629 
4.00 0.821 2.248 
12.25 38.411 8.518 
24.00 0.039 0.021 
 
B.  
Model Parameter 
CER-AP TLCS-AP 
Cmax (µg/mL) 10.610 26.676 
Tmax (h) 0.25 0.25 
T1/2 (h) 1.0 1.1 
AUC(0-inf) (µg.h/mL) 19.910 42.030 
AUC(0-inf)/D (µg.h/mL) 39.82 84.06 
% Extrapolation 6 9 
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Table 2. Effects of I-BET-762A on serum cytokines at 24 h in TLCS-AP. TLCS-AP was induced by retrograde 
infusion of 3 mM TLCS into the biliopancreatic duct, and I-BET-762 (30 mg/kg, i.p.) was given at the time of 
disease induction with a second dose 12 h later.  
Cytokines 
(pg/mL) 
 
Sham 
(n = 4) 
TLCS 
(n = 8) 
TLCS + I-BET-762A 
(n = 8) 
IL-1β 2.8 ± 0.6 2.4 ± 0.3 2.9 ± 0.1 
IL-6 62.5 ± 6.3 517.2 ± 142.1* 146.3 ± 71.0# 
IL-10 10.6 ± 0.2 78.7 ± 32.0* 11.6 ± 1.5# 
CCL2 34.3 ± 17.2 169.4 ± 129.7* 22.7 ± 15.6# 
CXCL1 130.9 ± 44.2 1623.8 ± 613.0* 192.6 ± 62.6# 
 
*P <0.01 sham versus TLCS-AP; #P <0.01 TLCS-AP versus TLCS-AP plus I-BET-762; TLCS, taurolithocholic 
acid 3-sulphate disodium salt; Values are means ± SE of 4-8 mice.  
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Table 3. Effects of I-BET-762A on serum cytokines at 24 h in FAEE-AP.  FAEE-AP was induced by 2 
intraperitoneal (i.p.) injection of ethanol (1.35 g/kg) and palmitoleic acid (POA, 150 mg/kg) at 1 h apart and I-
BET-762 (30 mg/kg, i.p.) was given at the time of disease induction with a second dose 12 h later. 
Cytokines 
(pg/mL) 
 
Saline 
(n = 4) 
Ethanol 
(n = 6) 
FAEE-AP 
(n = 6) 
FAEE-AP + I-BET-762A 
(n = 6) 
IL-1β 3.0 ± 0 2.3 ± 0.2 2.5 ± 0.2 2.3 ± 0.2 
IL-6 21.5 ± 2.1 24.8 ± 2.0 3807.6 ±1913.3* 24.9 ± 4.2# 
IL-10 12.4± 0.9 10.8 ± 0.3 82.8 ± 32.4* 10.0 ±1.0# 
CCL2 9.1± 0.8 9.1 ± 0.8 121.2 ± 73.6* 12.0 ± 2.9# 
CXCL1 62.6 ± 11.7 139.4 ± 45.6* 1477.0 ± 444.2* 172.6 ± 40.6# 
 
*P <0.01 saline versus ethanol or ethanol/POA group; #P <0.01 ethanol/POA versus ethanol/POA plus I-BET-
762 group; POA, palmitoleic acid; values are means ± SE of 4-6 mice.  
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Table 4. Effects of I-BET-762A on serum cytokines in CER-AP at 24 h. CER-AP was induced 12 hourly 
intraperitoneal (i.p.) injections of carerulein (50 µg/kg), and I-BET-762 (30 mg/kg, i.p.), given at the time of 
disease induction and the second dose 12 h later.  
 
Cytokines 
(pg/mL) 
 
Saline 
(n = 4) 
Caerulein 
(n = 8) 
Caerulein + I-BET-762A 
(n = 8) 
IL-1β 3.1 ± 0.5 3.0 ± 0.3 3.1 ± 0.5 
IL-6 21.0 ± 4.7 33.0 ± 3.0* 66.0 ± 11.4# 
IL-10 11.5 ± 1.3 11.5 ± 0.7 16.3 ± 2.1# 
CCL2 8.0 ± 0.7 10.4 ± 0.5* 17.0 ± 5.0# 
CXCL1 127.4 ± 74.1 290.1 ± 55.6* 442.6 ± 77.7# 
 
*P <0.05 saline versus caerulein; #P <0.05 caerulein versus caerulein plus I-BET-762 group; Values are means 
± SE of 4-8 mice. 
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FIGURE LEGENDS 
 
Figure 1. Protective effects of I-BET-762 on biochemical markers in TLCS-AP. Retrograde infusion of 3 mM 
TLCS into the biliopancreatic duct resulted in a significant elevation of (A) serum amylase, (B) pancreatic and 
(C) lung myeloperoxidase (MPO) activity. Control mice received sham operation with ductal saline infusion. 
Mice were sacrificed 24 h after ductal infusion. Intraperitoneal administration of 30 mg/kg I-BET-762 
significantly reduced serum amylase and lung MPO activity, with a trend to decrease pancreatic MPO activity. 
TLCS, taurolithocholic acid 3-sulphate disodium salt. *P < 0.05 sham versus TLCS group, #P < 0.05 TLCS 
versus TLCS plus I-BET-762 group. Values are mean ± SE of 6-11 mice.  
Figure 2. Protective effects of I-BET-762 on histopathological parameters in TLCS-AP. (A) Representative 
H&E images from pancreatic histopathology slides from sham, TLCS and TLCS plus I-BET-762 groups. (B) 
Histopathological scores: (i) overall histopathological score and its breakdown components: (ii) oedema, (iii) 
inflammation and (iii) necrosis. I-BET-762 significantly reduced overall and edema scores, with a trend to 
decrease inflammation and necrosis scores. *P < 0.05 sham versus TLCS group, #P < 0.05 TLCS versus TLCS 
plus I-BET-762 group. Values are mean ± SE of 6-12 mice. Magnification × 200.  
Figure 3. Protective effects of I-BET-762 on biochemical markers in FAEE-AP. Two intraperitoneal (i.p.) 
injection of ethanol (1.35 g/kg) and palmitoleic acid (POA, 150 mg/kg) at 1 h apart caused marked elevation of 
(A) serum amylase, (B) pancreatic trypsin activity, (C) pancreatic and (D) lung myeloperoxidase (MPO) 
activity. Control mice received the same regimen of normal saline or ethanol.  Mice were sacrificed 24 h after 
the first injection of ethanol/POA. Intraperitoneal administration of 30 mg/kg I-BET-762 significantly reduced 
serum amylase, pancreatic trypsin and MPO activity. *P < 0.05 saline versus ethanol or ethanol/POA group, #P 
< 0.05 ethanol/POA versus ethanol/POA plus I-BET-762 group. Values are mean ± SE of 6-10 mice.  
Figure 4. Protective effects of I-BET-762 on histopathological parameters in FAEE-AP. (A) Representative 
H&E images from pancreatic histopathology slides from saline, ethanol, ethanol/palmitoleic acid (POA), and 
ethanol/POA plus I-BET-762 groups. (B) Histopathological scores: (i) overall histopathological score and its 
breakdown components: (ii) oedema, (iii) inflammation and (iii) necrosis. I-BET-762 significantly reduced 
overall, oedema and inflammation scores, with a trend to decrease necrosis. *P < 0.05 saline versus ethanol or 
ethanol/POA group, #P < 0.05 ethanol/POA versus ethanol/POA plus I-BET-762 group. Values are mean ± SE 
of 6 mice. Magnification × 200.  
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Figure 5. Effects of I-BET-762 on biochemical markers in CER-AP. Twelve hourly introperitoneal injections of 
carerulein (50 µg/kg) resulted in significant elevation of (A) serum amylase, (B) pancreatic trypsin activity, (C) 
pancreatic and (D) lung myeloperoxidase (MPO) activity. Control mice received the same regimen of normal 
saline. Mice were sacrificed 24 h after the first injection of caerulein. Intraperitoneal administration of 30 mg/kg 
I-BET-762 had no protective effects, with a trend to increase biochemical parameters. *P < 0.05 control versus 
caerulein group. Values are mean ± SE of 6-12 mice.  
Figure 6. Effects of I-BET-762 on histopathological parameters in CER-AP. (A) Representative H&E images 
from pancreatic histopathology slides from saline, caerulein and caerulein plus I-BET-762 groups. (B) 
Histopathological scores: (i) overall histopathological score and its breakdown components: (ii) oedema, (iii) 
inflammation and (iii) necrosis. I-BET-762 had no protective effects on pancreatic damage with a trend to 
increase the scores. *P < 0.05 control versus caerulein group. Values are mean ± SE of 6-9 mice. Magnification 
× 200.  
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